BiotechTube

Axatilimab + Azacitidine

Phase 1/2Recruiting
0 watching 0 views this week💤 Quiet
38
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atypical Chronic Myeloid Leukemia

Conditions

Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myeloproliferative Neoplasm

Trial Timeline

Aug 2, 2024 → Oct 31, 2028

NCT ID
NCT06523556

About Axatilimab + Azacitidine

Axatilimab + Azacitidine is a phase 1/2 stage product being developed by Incyte for Atypical Chronic Myeloid Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06523556. Target conditions include Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm.

Hype Score Breakdown

Clinical
13
Activity
8
Company
7
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06523556Phase 1/2Recruiting

Competing Products

18 competing products in Atypical Chronic Myeloid Leukemia

See all competitors
ProductCompanyStageHype Score
CrovalimabChugai PharmaceuticalPhase 3
77
CrovalimabChugai PharmaceuticalPhase 3
77
DuloxetineEli LillyApproved
85
Teriparatide 20 mcgEli LillyPhase 3
77
BaricitinibEli LillyPre-clinical
23
RavulizumabAstraZenecaPre-clinical
23
EculizumabAstraZenecaPhase 3
77
IptacopanNovartisPhase 3
77
Iptcaopan 200 mgNovartisPhase 3
77
IptacopanNovartisPhase 3
77
Ropeginterferon Alfa-2BPharmaEssentiaPhase 2
51
CCX168AmgenPhase 2
51
Tazemetostat + Nivolumab + IpilimumabBristol Myers SquibbPhase 1/2
40
CemdisiranAlnylam PharmaceuticalsPhase 2
49
cemdisiran + PlacebosAlnylam PharmaceuticalsPhase 2
49
Gemcitabine + PaxalisibPacific BiosciencesPhase 2
44
Apatinib MesylateBrain BiotechPre-clinical
15
azurin-derived cell-penetrating peptide p28Brain BiotechPhase 1
25

Other Products from Incyte

ruxolitinib creamApproved
82
Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3
74
Povorcitinib + PlaceboPhase 3
74
Ruxolitinib Cream + Vehicle CreamPhase 3
74
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3
74